Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.8% - Should You Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s share price traded up 6.8% on Friday . The company traded as high as $24.94 and last traded at $24.82. 12,107 shares were traded during mid-day trading, a decline of 95% from the average session volume of 254,904 shares. The stock had previously closed at $23.25.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ELVN shares. HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird boosted their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, November 15th.

Enliven Therapeutics Trading Up 9.3 %

The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -13.38 and a beta of 1.02. The firm's 50-day moving average is $26.79 and its 200 day moving average is $24.15.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CEO Samuel Kintz sold 924 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $27,720.00. Following the completion of the sale, the chief executive officer now owns 1,002,892 shares of the company's stock, valued at approximately $30,086,760. This represents a 0.09 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 4,250 shares of the firm's stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 129,195 shares of company stock worth $3,581,772. Company insiders own 29.20% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently modified their holdings of the company. Quest Partners LLC lifted its holdings in Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company's stock valued at $37,000 after buying an additional 742 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Enliven Therapeutics by 64.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company's stock worth $232,000 after acquiring an additional 3,559 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics in the 3rd quarter valued at about $256,000. Verition Fund Management LLC bought a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at about $271,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $322,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.